Home

Laura Hamill

CIK 1751804 · EVP, Worldwide Commercial Ops · last filed 2026-09-02

Laura Hamill is an EVP, Worldwide Commercial Ops who has filed 31 SEC Form 4 insider transactions across 8 companies since 2018. The most recent filing shows the insider had shares withheld for taxes covering $411.8K of JAZZ on Sep 2, 2026. Current disclosed insider exposure totals $3.1M across reported positions. 6 SEC filings were submitted jointly with ANAPTYSBIO, INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.11M

Companies

8

Total Filings

31

Lifetime Open-Market Net

$0

Filer Profile

Reported Address
5147 N TAMANAR WAY
PARADISE VALLEY, AZ 85253
Related Filers
ANAPTYSBIO, INC — 6 joint filings, latest 2023-01-10
GILEAD SCIENCES, INC. — 4 joint filings, latest 2019-05-10
Scilex Holding Co — 2 joint filings, latest 2023-01-17
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
JAZZ Director 6,832 $237.95 $1.63M $0 5 2026-09-02
FATE Director — $2.35 — $0 1 2026-06-15
Y-mAbs Therapeutics, Inc. (YMAB) Delisted Director 30,905 $8.61 $266.1K $0 6 2025-07-02
PARDES BIOSCIENCES, INC. (PRDS) Delisted Director — $2.16 — $0 4 2023-08-31
SCLXW Director — $0.09 — $0 1 2023-01-17
ANAB Director — $51.00 — $0 5 2023-01-10
ACCELERON PHARMA INC (XLRN) Delisted Director 0 $178.75 $0 $0 3 2021-11-22
GILD EVP, Worldwide Commercial Ops 9,840 $150.93 $1.49M $0 3 2019-05-10

Recent Filings

31 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-09-02 JAZZ Tax (F) −1,706 -$411.8K EDGAR
2026-08-31 JAZZ Notice (144) −3,507 -$857.6K EDGAR
2026-08-07 JAZZ Grant (A) +1,605 $0 EDGAR
2026-08-07 JAZZ Grant (A) +1,605 $0 EDGAR
2026-06-15 FATE Grant (A) — $0 EDGAR
2025-09-19 — Mixed −30,905 -$50.1K
2025-08-11 JAZZ Mixed +1,702 -$200.8K EDGAR
2025-08-08 JAZZ Notice (144) −3,731 -$417.9K EDGAR
2025-07-02 Y-mAbs Therapeutics, Inc. (YMAB) Delisted Grant (A) +25,080 $0 EDGAR
2024-08-06 JAZZ Grant (A) +3,731 $0 EDGAR
Showing 1–10 of 31
Page 1 of 4
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.